UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison

Haematologica (Roma), 2024-06, Vol.109 (6), p.1866

2024

Volltextzugriff (PDF)

P618: LONG‐TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B‐CELL MALIGNANCIES

HemaSphere, 2023-08, Vol.7 (S3), p.e6206253-n/a

2023

Volltextzugriff (PDF)

Neuropeptide Y acts at Y1 receptors in the rostral ventral medulla to inhibit neuropathic pain

Pain (Amsterdam), 2007-09, Vol.131 (1), p.83-95

2007

Volltextzugriff (PDF)

Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia

Leukemia & lymphoma, 2021-08, Vol.62 (10), p.2342-2351

2021

Volltextzugriff (PDF)

Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis

Clinical therapeutics, 2020-10, Vol.42 (10), p.1955-1974.e15

2020

Volltextzugriff (PDF)

Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma

Clinical therapeutics, 2019-11, Vol.41 (11), p.2357-2379.e1

2019

Volltextzugriff (PDF)

Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Blood, 2021-11, Vol.138 (Supplement 1), p.1553-1553

2021

Volltextzugriff (PDF)

Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7513-7513

2023

Volltextzugriff (PDF)

Right atrial dimension-pressure relation during volume expansion is unaltered by pregnancy in the rat

American journal of physiology. Heart and circulatory physiology, 2005-01, Vol.288 (1), p.H116-H120

2005

Volltextzugriff (PDF)

MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

Future oncology (London, England), 2022-10, Vol.18 (33), p.3689-3699

2022

Volltextzugriff (PDF)

CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S520-S520

2023

Volltextzugriff (PDF)

POSTER: CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S229-S229

2023

Volltextzugriff (PDF)

Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies

Acta haematologica, 2024-06, p.1-17

2024

Volltextzugriff (PDF)

Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer

Medicine (Baltimore), 2017-07, Vol.96 (27), p.e7223

2017

Volltextzugriff (PDF)

Comparative healthcare costs in patients with metastatic melanoma in the USA

Melanoma research, 2015-08, Vol.25 (4), p.312-320

2015

Volltextzugriff (PDF)

Phase II study of vemurafenib in patients with locally advanced, unresectable stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.9075-9075

2014

Volltextzugriff (PDF)

BRAF V600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study

OncoTargets and therapy, 2017-02, Vol.10, p.965-971

2017

Volltextzugriff (PDF)

mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study

OncoTargets and therapy, 2017-01, Vol.10, p.965

2017

Volltextzugriff (PDF)

BRAFV600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study

OncoTargets and therapy, 2017-01, Vol.10, p.965-971

2017

Volltextzugriff (PDF)

Treatment patterns and outcomes in BRAF V600E mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.9035-9035

2014

Volltextzugriff (PDF)

Treatment patterns and outcomes in BRAF V600E‐mutant melanoma patients with brain metastases receiving vemurafenib in the real‐world setting

Cancer medicine (Malden, MA), 2015-08, Vol.4 (8), p.1205-1213

2015

Volltextzugriff (PDF)

Right atrial dimension-pressure relation during volume expansion is unaltered by pregnancy in the rat

American journal of physiology. Heart and circulatory physiology, 2005, Vol.57 (1), p.H116-H120

2005

Volltextzugriff (PDF)

Neuropeptide Y acts at Yl receptors in the rostral ventral medulla to inhibit neuropathic pain

Pain (Amsterdam), 2007, Vol.131 (1-2), p.83-95

2007

Volltextzugriff (PDF)

INTEGRATION OF LOGICAL FEATURES WITH NEURAL NETWORKS FOR CONTROLLED VS UNCONTROLLED FIRE CLASSIFICATION: A COMPARATIVE STUDY

Indian journal of computer science and engineering, 2023-08, Vol.14 (4), p.674-683

2023

Volltextzugriff (PDF)

TCT-571 Clinical Outcomes of Biodegradable-Polymer Coated Sirolimus-Eluting Stent in Unselected Patients with Long Coronary Lesions: LONG-FLEX Registry

Journal of the American College of Cardiology, 2015-10, Vol.66 (15), p.B232-B232

2015

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(9)
Science & Technology
(9)
Humans
(6)
Antineoplastic Agents - Therapeutic Use
(5)
Male
(5)
Oncology
(5)
Female
(4)
Middle Aged
(4)
Treatment Outcome
(4)
Acalabrutinib
(3)
Aged
(3)
Kinases
(3)
Mutation
(3)
Patients
(3)
Sulfonamides - Therapeutic Use
(3)
Survival
(3)
Vemurafenib
(3)
Adult
(2)
Aged, 80 And Over
(2)
Animals
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison

P618: LONG‐TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B‐CELL MALIGNANCIES

Neuropeptide Y acts at Y1 receptors in the rostral ventral medulla to inhibit neuropathic pain

Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia

Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis

Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma

Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies

Right atrial dimension-pressure relation during volume expansion is unaltered by pregnancy in the rat

MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies

POSTER: CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies

Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies

Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer

Comparative healthcare costs in patients with metastatic melanoma in the USA

Phase II study of vemurafenib in patients with locally advanced, unresectable stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E

BRAF V600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study

mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study

BRAFV600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study

Treatment patterns and outcomes in BRAF V600E mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting

Treatment patterns and outcomes in BRAF V600E‐mutant melanoma patients with brain metastases receiving vemurafenib in the real‐world setting

Right atrial dimension-pressure relation during volume expansion is unaltered by pregnancy in the rat

Neuropeptide Y acts at Yl receptors in the rostral ventral medulla to inhibit neuropathic pain

INTEGRATION OF LOGICAL FEATURES WITH NEURAL NETWORKS FOR CONTROLLED VS UNCONTROLLED FIRE CLASSIFICATION: A COMPARATIVE STUDY

TCT-571 Clinical Outcomes of Biodegradable-Polymer Coated Sirolimus-Eluting Stent in Unselected Patients with Long Coronary Lesions: LONG-FLEX Registry

Suchergebnisse filtern